Different spatiotemporal trajectories of the p-Tau accumulation are known in AD and other tauopathies, the future availability of cerebral Tau PET being of great value for the differential diagnosis “in vivo” of these diseases [24]. This evidence concerns the gene MAPT and Alzheimer disease.